AQR Capital Management, LLC and AQR Capital Management Holdings, LLC filed an amended beneficial ownership statement with the SEC on November 12, 2026, disclosing a combined holding of 672,616 shares of Aldeyra Therapeutics, Inc. common stock as of September 30, 2026.

Key Highlights

  • Reporting persons: AQR Capital Management, LLC (investment adviser) and its parent, AQR Capital Management Holdings, LLC (holding company), both organized in the United States.
  • Shares held: Each reporting person lists 672,616 shares of Aldeyra Therapeutics common stock, $0.001 par value, beneficially owned as of September 30, 2026.
  • Percent of class: The 672,616 shares represent 1.11% of Aldeyra Therapeutics' outstanding common stock, according to the filing.
  • Voting and dispositive power: Both entities report zero sole voting power and zero sole dispositive power; shared voting and shared dispositive power are each listed at 672,616 shares.
  • Amendment number: This is Amendment No. 1 to a previously filed statement, triggered by an event dated September 30, 2026.
  • Ownership threshold: The filing discloses ownership of 5 percent or less of the class, and Item 6 is marked "Not Applicable," indicating no ownership on behalf of another person exceeding 5 percent.

AQR's Disclosed Position in Aldeyra Therapeutics Common Stock

According to the filing, AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, with both entities headquartered at One Greenwich Plaza, Suite 130, Greenwich, Connecticut 06830. The statement was signed by Henry Parkin as Authorized Signatory for both entities on November 12, 2026. The filing identifies AQR Capital Management, LLC as an investment adviser (type "IA") and AQR Capital Management Holdings, LLC as a holding company (type "HC").

Aldeyra Therapeutics, Inc., the issuer, is a clinical-stage biopharmaceutical company whose common stock carries a par value of $0.001 per share and CUSIP number 01438T106. The company's principal executive offices are listed in the filing as 23 Bradford Street, Suite 1, Concord, Massachusetts 01742. The filing certified, in the words of the document, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

Because AQR Capital Management Holdings, LLC is the parent of AQR Capital Management, LLC, both entities report the same aggregate beneficial ownership figure of 672,616 shares. The filing notes that the two parties agreed by exhibit that this statement is filed jointly on behalf of each of them, consistent with the parent-subsidiary relationship described in the document.

What Was Disclosed

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC disclosed a combined beneficial ownership of 672,616 shares, equal to 1.11% of Aldeyra Therapeutics' common stock, with all voting and dispositive power held on a shared basis as of September 30, 2026.